obesity

Integrative approach reveals key inflammatory drivers of severe obesity

Severe obesity — a condition of being 100 pounds or more overweight — has doubled in the United States over the past two decades to 9.2%, with the greatest increases among women and Latino populations.

Weight-loss surgery associated with reduced dementia

An observational study found that bariatric surgery was associated with 63% reduced risk of Alzheimer’s disease and related dementias.

GLP-1 medicines are focus of Discovery Lecture on Nov. 21

Daniel Drucker, MD, a pioneering scientist whose research contributed to the development of the blockbuster GLP-1 medicines used to treat diabetes and obesity, was listed by TIME magazine as one of the 100 Most Influential People of 2024.

Greenlight study demonstrates effective early intervention in preventing childhood obesity

Researchers examined if childhood obesity could be prevented by leveraging a combination of health behavior counseling offered by pediatric primary care clinicians and modern digital health literacy tools.

Blockbuster obesity drugs also may slow kidney disease

The report supports previous clinical trials that found the GLP-1 receptor agonist drug semaglutide reduced kidney disease progression in patients with Type 2 diabetes.

Obesity-cancer connection discovery suggests strategies for improving immunotherapy 

The study reported in the journal Nature provides a mechanistic explanation for the “obesity paradox” — that obesity can contribute to cancer progression but also improve response to immunotherapy.

1 2 3 7